DAC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-21. Numbers and descriptions here follow the published literature rather than marketing material.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Monazite geochronology can also reveal igneous differentiation events such as magma mixing, where the magma chamber is evolved into a different composition. Isomorphous substitution is one of the examples. It is a form of substitution in which one element is replaced by another without changing the crystal structure. In the case of monazite, the rare earth elements are replaced by Ca and Th.
Principle 1: Conduct a hazard analysis. Principle 2: After assessing all the processing steps, the Critical control point (CCP) is controlled. CCP are points which determine and control significant hazards in a food manufacturing process. Principle 3: Set up critical limits in order to ensure that the hazard identified is being controlled effectively. Principle 4: Establish a system so as to monitor the CCP. Principle 5: Establish corrective actions where the critical limit has not been met. Appropriate actions need to be taken which can be on a short or long-term basis. All records must be sustained accurately. Principle 6: Establish authentication procedures so as to confirm if the principles imposed by HACCP documents are being respected effectively and all records are being taken. Principle 7: Analyze if the HACCP plan are working effectively.
One interview in 2015 with the then Director of the White House Office of National Drug Control Policy under the Obama administration, Michael Botticelli, where he states that because opioid users are predominantly 'white and middle class', they "know how to call a legislator, [and] fight with their insurance company." In October 2017, Marino withdrew his nomination after it was reported that his relationship with the drug industry might be a conflict of interest. In July 2017, FDA commissioner Scott Gottlieb stated that for the first time, pharmacists, nurses, and physicians would have training made available on appropriate prescribing of opioid medicines, because opioid addiction had become the "FDA's biggest crisis". Trump nominated his then deputy chief-of-staff, James Carroll as the acting director of the Office of National Drug Control Policy in 2018. In January 2019, Carroll was approved by the Senate. In April 2017, the Department of Health and Human Services announced their "Opioid Strategy" consisting of five aims:
===== Heart ===== In 2024, researchers were able to 3D print a human heart with a biphasic bioink containing pluripotent stem cells (PSC). The technique they proposed and tested would first print the external features of the organ before then printing the internal features such as internal vasculature inside the previously printed structure. Both sets of printing were performed by extruding the bioink filament into layered structures set in a microgel medium. This technique was called the "SPIRIT" technique and allowed for the printing of a full-sized heart at significantly faster speeds than previous methods.
Sources: en.wikipedia.org
The bird in the hand may be examined and measurements can be made, including standard lengths and weights. Feather moult and skull ossification provide indications of age and health. Sex can be determined by examination of anatomy in some sexually nondimorphic species. Blood samples may be drawn to determine hormonal conditions in studies of physiology, identify DNA markers for studying genetics and kinship in studies of breeding biology and phylogeography. Blood may also be used to identify pathogens and arthropod-borne viruses. Ectoparasites may be collected for studies of coevolution and zoonoses. In many cryptic species, measurements (such as the relative lengths of wing feathers in warblers) are vital in establishing identity. Captured birds are often marked for future recognition. Rings or bands provide long-lasting identification, but require capture for the information on them to be read. Field-identifiable marks such as coloured bands, wing tags, or dyes enable short-term studies where individual identification is required. Mark and recapture techniques make demographic studies possible. Ringing has traditionally been used in the study of migration. In recent times, satellite transmitters provide the ability to track migrating birds in near-real time. Techniques for estimating population density include point counts, transects, and territory mapping. Observations are made in the field using carefully designed protocols and the data may be analysed to estimate bird diversity, relative abundance, or absolute population densities.
==== MeSH D13.570.800 – ribonucleosides ==== MeSH D13.570.800.096 – adenosine MeSH D13.570.800.096.250 – adenosine-5'-(n-ethylcarboxamide) MeSH D13.570.800.096.262 – s-adenosylhomocysteine MeSH D13.570.800.096.264 – s-adenosylmethionine MeSH D13.570.800.096.300 – 2-chloroadenosine MeSH D13.570.800.096.300.200 – cladribine MeSH D13.570.800.096.500 – isopentenyladenosine MeSH D13.570.800.096.630 – phenylisopropyladenosine MeSH D13.570.800.286 – cytidine MeSH D13.570.800.286.300 – azacitidine MeSH D13.570.800.330 – dichlororibofuranosylbenzimidazole MeSH D13.570.800.410 – formycins MeSH D13.570.800.410.200 – coformycin MeSH D13.570.800.453 – guanosine MeSH D13.570.800.453.500 – nucleoside q MeSH D13.570.800.573 – inosine MeSH D13.570.800.573.130 – didanosine MeSH D13.570.800.573.450 – inosine pranobex MeSH D13.570.800.573.900 – thioinosine MeSH D13.570.800.573.900.500 – methylthioinosine MeSH D13.570.800.790 – ribavirin MeSH D13.570.800.810 – showdomycin MeSH D13.570.800.840 – toyocamycin MeSH D13.570.800.850 – tubercidin MeSH D13.570.800.892 – uridine MeSH D13.570.800.892.176 – azauridine MeSH D13.570.800.892.250 – 3-deazauridine MeSH D13.570.800.892.628 – pseudouridine MeSH D13.570.800.892.800 – tetrahydrouridine MeSH D13.570.800.892.829 – thiouridine
=== Structural domains === All of the isoforms of CaMKII have: a catalytic domain, an autoinhibitory regulatory domain, a variable segment, and a self-association domain. The catalytic domain binds ATP and substrate proteins; it is responsible for the transfer of phosphate from ATP to Ser or Thr residues in the substrate proteins. The autoinhibitory regulatory domain features a pseudosubstrate site, which binds to the catalytic domain and blocks its ability to phosphorylate proteins. The structural feature that governs this autoinhibition is the Threonine 286 residue. Phosphorylation of this site will permanently activate the CaMKII enzyme. Once the Threonine 286 residue has been phosphorylated, the inhibitory domain is blocked from the pseudosubstrate site. This effectively blocks autoinhibition, allowing for permanent activation of the CaMKII enzyme. This enables CaMKII to be active, even in the absence of calcium and calmodulin. The other two domains in CaMKII are the variable and self-association domains. Differences in these domains contribute to the various CaMKII isoforms. The self-association domain (CaMKII AD) is found at the C terminus, the function of this domain is the assembly of the single proteins into large (8 to 14 subunits) multimers.
As treasurer, Kennedy pushed for tougher ethical standards in state contracting reform. In 2007, he called for a full investigation into all contracts signed in the wake of Hurricane Katrina after media investigations revealed that one FEMA contractor allegedly engaged in profiteering by misrepresenting timesheets and hourly rates. Kennedy also urged Governor Blanco to ban family members of state officials from securing construction contracts during the rebuilding effort. In 2013, Kennedy reported 30 Louisiana nonprofits to the legislative auditor's office after they failed to file financial reports. In 2014, he launched an investigation into Act 859, an unconstitutional state retirement bill that benefited state police chief Mike Edmonson and one other state trooper. Kennedy said he received hundreds of emails from state employees who found the legislation unfair and claimed that the state's police officer retirement fund was underwater because "for years the legislature passed special interest legislation like this to help a select few". In 2014, Kennedy urged state prosecutors to start pressing charges against people who committed food stamp fraud. Kennedy noted that more than $1.1 million in food stamp debit cards were sent to people in jails, $107,000 was sent to ineligible felons, and $2 million was spent outside the state—implying that the funds were likely sent to nonresidents.
The first prefrontal leucotomy in the United States was performed at the George Washington University Hospital, on 14 September 1936, by the neurologist Walter Freeman, and his friend and colleague, the neurosurgeon James W. Watts. Freeman had first encountered Moniz at the London-hosted Second International Congress of Neurology in 1935, where he had presented a poster exhibit of the Portuguese neurologist's work on cerebral angiography. Fortuitously occupying a booth next to Moniz, Freeman, delighted by their chance meeting, formed a highly favourable impression of Moniz, later remarking upon his "sheer genius". According to Freeman, if they had not met in person, it is highly unlikely that he would have ventured into the domain of frontal lobe psychosurgery. Freeman's interest in psychiatry was the natural outgrowth of his appointment in 1924 as the medical director of the Research Laboratories of the Government Hospital for the Insane in Washington, known colloquially as St Elizabeth's. Freeman, who favoured an organic model of mental illness causation, spent the next several years exhaustively, yet ultimately fruitlessly, investigating a neuropathological basis for insanity. Chancing upon a preliminary communication by Moniz on leucotomy in the spring of 1936, Freeman initiated a correspondence in May of that year. Writing that he had been considering psychiatric brain surgery previously, he informed Moniz that, "having your authority I expect to go ahead".
Sources: en.wikipedia.org
In anatomy and histology, the term wandering cell (or ameboid cell) is used to describe cells that are found in connective tissue, but are not fixed in place. This term is used occasionally and usually refers to blood leukocytes (which are not fixed and organized in solid tissue) in particular mononuclear phagocytes. Frequently, the term refers to circulating macrophages and has been used also for stationary macrophages fixed in tissues (histiocytes), which are sometimes referred to as "resting wandering cells".
=== Diet === There is varying evidence about the importance of saturated fat in the development of myocardial infarctions. Eating polyunsaturated fat instead of saturated fats has been shown in studies to be associated with a decreased risk of myocardial infarction, while other studies find little evidence that reducing dietary saturated fat or increasing polyunsaturated fat intake affects heart attack risk. Dietary cholesterol does not appear to have a significant effect on blood cholesterol and thus recommendations about its consumption may not be needed. Trans fats do appear to increase risk. Acute and prolonged intake of high quantities of alcoholic drinks (3–4 or more daily) increases the risk of a heart attack.
A number of people, starting with Gerald Kulcinski in 1986, have proposed to explore the Moon, mine lunar regolith, and use the helium-3 for fusion. Liquid helium-4 can be cooled to about 1 K (−272.15 °C; −457.87 °F) using evaporative cooling in a 1-K pot. Similar cooling of helium-3, which has a lower boiling point, can achieve about 0.2 kelvin in a helium-3 refrigerator. Equal mixtures of liquid 3He and 4He below 0.8 K separate into two immiscible phases due to their dissimilarity (they follow different quantum statistics: helium-4 atoms are bosons while helium-3 atoms are fermions). Dilution refrigerators use this immiscibility to achieve temperatures of a few millikelvins. It is possible to produce exotic helium isotopes, which rapidly decay into other substances. The shortest-lived heavy helium isotope is the unbound helium-10 with a half-life of 2.6(4)×10−22 s. Helium-6 decays by emitting a beta particle and has a half-life of 0.8 seconds. Helium-7 and helium-8 are created in certain nuclear reactions. Helium-6 and helium-8 are known to exhibit a nuclear halo.
The lymphatic vessels, also called lymph vessels, are thin-walled vessels that conduct lymph between different parts of the body. They include the tubular vessels of the lymph capillaries, and the larger collecting vessels – the right lymphatic duct and the thoracic duct (the left lymphatic duct). Lymph capillaries are primarily responsible for the absorption of interstitial fluid from the tissues. Lymph vessels propel the absorbed fluid forward into the larger collecting ducts, where it ultimately returns to the bloodstream via one of the subclavian veins. The tissues of the lymphatic system are responsible for maintaining the balance of the body fluids. Its network of capillaries and collecting lymphatic vessels efficiently drain and transport extravasated fluid, along with proteins and antigens, back to the circulatory system. Numerous intraluminal valves in the vessels ensure a unidirectional lymph flow without reflux. Two valve systems, a primary and a secondary valve system, are used to achieve this unidirectional flow. The capillaries are blind-ended; the valves at the ends of capillaries use specialised junctions together with anchoring filaments to allow a unidirectional flow to the primary vessels. When interstitial fluid increases, it causes swelling that stretches collagen fibers anchored to adjacent connective tissue, opening the unidirectional valves at the ends of these capillaries and facilitating the entry and subsequent drainage of excess lymph fluid.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.